Literature DB >> 8137457

Clinical pharmacokinetics of carboplatin in children.

R Riccardi1, A Riccardi, A Lasorella, C Di Rocco, G Carelli, A Tornesello, T Servidei, A Iavarone, R Mastrangelo.   

Abstract

The present study was undertaken to evaluate in children the plasma pharmacokinetics of free carboplatin given at different doses and schedules and to evaluate the inter- and intrapatient variability and the possible influence of schedule on drug exposure. A total of 35 children (age range, 1-17 years) with malignant tumors were studied. All patients had normal renal function (creatinine clearance corrected for surface body area, above 70 ml min-1 m-2; range, 71-151 ml min-1 m-2) and none had renal involvement by malignancy. Carboplatin was given at the following doses and schedules: 175, 400, 500, and 600 mg/m2 given as as a 1-h infusion; 1,200 mg/m2 divided into equal doses and infused over 1 h on 2 consecutive days; and 875 and 1,200 mg/m2 given as a 5-day continuous infusion. A total of 57 courses were studied. Carboplatin levels in plasma ultrafiltrate (UF) samples were measured both by high-performance liquid chromatography and by atomic absorption spectrophotometry. Following a 1-h infusion, carboplatin free plasma levels decayed biphasically; the disappearance half-lives, total body clearance, and apparent volume of distribution were similar for different doses. In children with normal renal function as defined by creatinemia and blood urea nitrogen (BUN) and creatinine clearance, we found at each dose studied a limited interpatient variability of the peak plasma concentration (Cmax) and the area under the concentration-time curve (AUC) and a linear correlation between the dose and both Cmax (r = 0.95) and AUC (r = 0.97). The mean value +/- SD for the dose-normalized AUC was 13 +/- 2 min m2 l-1 (n = 57).2+ The administration schedule does not seem to influence drug exposure, since prolonged i.v. infusion or bolus administration of 1,200 mg/m2 achieved a similar AUC (13.78 +/- 2.90 and 15.05 +/- 1.44 mg ml-1 min, respectively). In the nine children studied during subsequent courses a limited interpatient variability was observed and no correlation (r = 0.035) was found between AUC and subsequent courses by a multivariate analysis of dose, AUC, and course number. The pharmacokinetic parameters were similar to those previously reported in adults; however, a weak correlation (r = 0.52, P = 0.03) between carboplatin total body clearance and creatinine clearance varying within the normal range was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137457     DOI: 10.1007/bf00686504

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

1.  Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children.

Authors:  F Doz; L Brugières; G Bastian; E Quintana; J Lemerle; J M Zucker
Journal:  Med Pediatr Oncol       Date:  1990

2.  Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.

Authors:  D R Newell; R A Eeles; L A Gumbrell; F E Boxall; A Horwich; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion.

Authors:  J M Koeller; D L Trump; K D Tutsch; R H Earhart; T E Davis; D C Tormey
Journal:  Cancer       Date:  1986-01-15       Impact factor: 6.860

4.  Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report.

Authors:  P S Gaynon; L J Ettinger; D Moel; S E Siegel; E S Baum; W Krivit; G D Hammond
Journal:  Cancer Treat Rep       Date:  1987-11

5.  Pharmacokinetics of carboplatin after i.v. administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; J B Vermorken; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1987-12

6.  Phase I study of carboplatin (CBDCA) in children with cancer.

Authors:  D M Bacha; B Caparros-Sison; J A Allen; R Walker; C T Tan
Journal:  Cancer Treat Rep       Date:  1986-07

Review 7.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

8.  High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine.

Authors:  R C Gaver; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.

Authors:  K Takahashi; T Seki; K Nishikawa; S Minamide; M Iwabuchi; M Ono; S Nagamine; H Horinishi
Journal:  Jpn J Cancer Res       Date:  1985-01
View more
  4 in total

1.  Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model.

Authors:  Kristoph Jahnke; Leslie L Muldoon; Csanad G Varallyay; Seth J Lewin; Dale F Kraemer; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2008-09-04       Impact factor: 12.300

2.  Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters.

Authors:  Mirjam E van de Velde; Emil den Bakker; Hester N Blufpand; Gertjan L Kaspers; Floor C H Abbink; Arjenne W A Kors; Abraham J Wilhelm; Richard J Honeywell; Godefridus J Peters; Birgit Stoffel-Wagner; Laurien M Buffart; Arend Bökenkamp
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

3.  In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.

Authors:  Susanna J E Veringa; Dennis Biesmans; Dannis G van Vuurden; Marc H A Jansen; Laurine E Wedekind; Ilona Horsman; Pieter Wesseling; William Peter Vandertop; David P Noske; GertJan J L Kaspers; Esther Hulleman
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

4.  Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonads.

Authors:  Caroline M Allen; Federica Lopes; Rod T Mitchell; Norah Spears
Journal:  Mol Hum Reprod       Date:  2020-03-26       Impact factor: 4.025

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.